Cargando…

1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study

BACKGROUND: Cancer has been a significant feature of the HIV epidemic from the beginning, being the most frequent Kaposi sarcoma (KS) and hematolymphoid malignancies. However, the behavior of these two diseases is limited in our context. The study aimed to determine the trends of cancer among HIV/AI...

Descripción completa

Detalles Bibliográficos
Autores principales: Parra-Lara, Luis Gabriel, Carlos Bravo, Juan, Eduardo Bravo, Luis, Rosso, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809428/
http://dx.doi.org/10.1093/ofid/ofz360.1129
_version_ 1783461985687437312
author Parra-Lara, Luis Gabriel
Carlos Bravo, Juan
Eduardo Bravo, Luis
Rosso, Fernando
author_facet Parra-Lara, Luis Gabriel
Carlos Bravo, Juan
Eduardo Bravo, Luis
Rosso, Fernando
author_sort Parra-Lara, Luis Gabriel
collection PubMed
description BACKGROUND: Cancer has been a significant feature of the HIV epidemic from the beginning, being the most frequent Kaposi sarcoma (KS) and hematolymphoid malignancies. However, the behavior of these two diseases is limited in our context. The study aimed to determine the trends of cancer among HIV/AIDS patients between 2011 and 2016. METHODS: A retrospective hospital-based study was conducted at Fundación Valle del Lili, Cali, Colombia. The study included HIV-positive patients diagnosed with cancer after infection. HIV registry was cross-linked with a population-based cancer registry to obtain IARC/WHO ICD-O-3 classification and follow-up information on all patients. A descriptive analysis of the variables was performed. Survival analysis was carried out using the Kaplan–Meier method. Differences between cancer survival were assessed through the log-rank test. RESULTS: From 2,051 HIV-positive patient’s records between 2011 and 2016, 95 patients were diagnosed with cancer after HIV infection. The median age was 43 years (IQR=33–57), and 88% were male. Types of cancer were: Kaposi’s sarcoma 17%, hematolymphoid malignancies 21% and other cancer 62%. The probability of cancer diagnosis after HIV diagnosis was 36.26% (CI 95% [26.53–46.05]) at one-year follow-up for all malignancies. Overall survival of the patients was 77.41% (CI 95% [64.76–86]) at 5 years follow-up, since HIV diagnostic. Hematolymphoid malignancies and KS survival were 50% (CI 95% [20.85–73.61]) and 65.63% (CI 95% [35.80–84.14]) at 5 years follow-up, respectively. There was a statistically significant difference between KS, hematolymphoid and other cancer cases survival (P = 0.0178). CONCLUSION: This study showed the role of HIV in cancer survival for KS and hematolymphoid malignancies mainly, in a developing country. It is necessary to join efforts in our context to reduce HIV cases and associated malignancies. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809428
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68094282019-10-28 1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study Parra-Lara, Luis Gabriel Carlos Bravo, Juan Eduardo Bravo, Luis Rosso, Fernando Open Forum Infect Dis Abstracts BACKGROUND: Cancer has been a significant feature of the HIV epidemic from the beginning, being the most frequent Kaposi sarcoma (KS) and hematolymphoid malignancies. However, the behavior of these two diseases is limited in our context. The study aimed to determine the trends of cancer among HIV/AIDS patients between 2011 and 2016. METHODS: A retrospective hospital-based study was conducted at Fundación Valle del Lili, Cali, Colombia. The study included HIV-positive patients diagnosed with cancer after infection. HIV registry was cross-linked with a population-based cancer registry to obtain IARC/WHO ICD-O-3 classification and follow-up information on all patients. A descriptive analysis of the variables was performed. Survival analysis was carried out using the Kaplan–Meier method. Differences between cancer survival were assessed through the log-rank test. RESULTS: From 2,051 HIV-positive patient’s records between 2011 and 2016, 95 patients were diagnosed with cancer after HIV infection. The median age was 43 years (IQR=33–57), and 88% were male. Types of cancer were: Kaposi’s sarcoma 17%, hematolymphoid malignancies 21% and other cancer 62%. The probability of cancer diagnosis after HIV diagnosis was 36.26% (CI 95% [26.53–46.05]) at one-year follow-up for all malignancies. Overall survival of the patients was 77.41% (CI 95% [64.76–86]) at 5 years follow-up, since HIV diagnostic. Hematolymphoid malignancies and KS survival were 50% (CI 95% [20.85–73.61]) and 65.63% (CI 95% [35.80–84.14]) at 5 years follow-up, respectively. There was a statistically significant difference between KS, hematolymphoid and other cancer cases survival (P = 0.0178). CONCLUSION: This study showed the role of HIV in cancer survival for KS and hematolymphoid malignancies mainly, in a developing country. It is necessary to join efforts in our context to reduce HIV cases and associated malignancies. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809428/ http://dx.doi.org/10.1093/ofid/ofz360.1129 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Parra-Lara, Luis Gabriel
Carlos Bravo, Juan
Eduardo Bravo, Luis
Rosso, Fernando
1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
title 1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
title_full 1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
title_fullStr 1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
title_full_unstemmed 1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
title_short 1266. Cancer among HIV-Positive Patients in Cali, Colombia: A Retrospective Hospital-Based Study
title_sort 1266. cancer among hiv-positive patients in cali, colombia: a retrospective hospital-based study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809428/
http://dx.doi.org/10.1093/ofid/ofz360.1129
work_keys_str_mv AT parralaraluisgabriel 1266canceramonghivpositivepatientsincalicolombiaaretrospectivehospitalbasedstudy
AT carlosbravojuan 1266canceramonghivpositivepatientsincalicolombiaaretrospectivehospitalbasedstudy
AT eduardobravoluis 1266canceramonghivpositivepatientsincalicolombiaaretrospectivehospitalbasedstudy
AT rossofernando 1266canceramonghivpositivepatientsincalicolombiaaretrospectivehospitalbasedstudy